文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌中人乳头状瘤病毒的连续基因分型:放化疗期间病毒组动态的初步观察

Serial Genotyping of the Human Papillomavirus in Cervical Cancer: An Insight Into Virome Dynamics During Chemoradiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-02-16

这项前瞻性研究纳入79例IB-IVB期接受根治性放化疗的宫颈癌患者,基线及第5周宫颈肿瘤拭子行鸟枪法宏基因组测序,按HPV型别分组。基线HPV 16、18、高危、低危阳性分别占42%、12%、25%、16%,8%阴性;除低危型外总体HPV病毒载量在放化疗期间下降。HPV 18及低危/阴性肿瘤与放化疗反应差相关。

要点

  • 宫颈肿瘤中较少研究的HPV型别具有临床意义。
  • HPV 18及低危/阴性肿瘤与放化疗反应差相关。
  • 本研究为探索性可行性研究,为更大规模瘤内HPV图谱研究提供框架。

核心结论

  • 宫颈肿瘤中较少见、研究较少的HPV型别具有临床意义。
  • HPV 18及低危/阴性肿瘤与放化疗反应差相关。
  • 本可行性研究为更大规模瘤内HPV图谱预测宫颈癌结局的研究提供框架。

研究设计与样本

  • 前瞻性研究纳入79例IB-IVB期接受根治性放化疗的宫颈癌患者。
  • 基线及第5周(调强放疗结束时)采集宫颈肿瘤拭子行鸟枪法宏基因组测序,经VirMAP工具处理识别所有已知HPV型别。
  • 数据按HPV组别(16、18、高危、低危)分类,采用独立t检验与Wilcoxon符号秩检验比较连续变量,χ2检验与Fisher精确检验比较分类变量。
  • 采用Kaplan-Meier生存建模并行log-rank检验。
  • 以定量聚合酶链反应验证VirMAP结果,采用受试者工作特征曲线与Cohen kappa评价。

主要发现

  • 基线时HPV 16、HPV 18、HPV高危、HPV低危阳性患者分别占42%、12%、25%、16%,8%为HPV阴性。
  • HPV型别与保险状态及放化疗反应相关。
  • HPV 16+及其他高危HPV+肿瘤患者较HPV 18及低危/HPV阴性肿瘤患者更可能获得放化疗完全缓解。
  • 除HPV低危型病毒载量外,总体HPV病毒载量在放化疗全程以下降为主。

局限性

  • 本可行性研究为探索性研究,作者提出需开展更大规模研究以验证瘤内HPV图谱预测宫颈癌结局的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Human papillomavirus (HPV) is the primary driver of cervical cancer. Although studies in other malignancies correlated peripheral blood DNA clearance with favorable outcomes, research on the prognostic value of HPV clearance in gynecologic cancers using intratumoral HPV is scarce. We aimed to quantify the intratumoral HPV virome in patients undergoing chemoradiation therapy (CRT) and associate this with clinical characteristics and outcomes. METHODS AND MATERIALS: This prospective study enrolled 79 patients with stage IB-IVB cervical cancer undergoing definitive CRT. Cervical tumor swabs collected at baseline and week 5 (end of intensity modulated radiation therapy) were sent for shotgun metagenome sequencing and processed via VirMAP, a viral genome sequencing and identification tool for all known HPV types. The data were categorized into HPV groups (16, 18, high risk [HR], and low risk [LR]). We used independent t tests and Wilcoxon signed-rank to compare continuous variables and χ2 and Fisher exact tests to compare categorical variables. Kaplan-Meier survival modeling was performed with log-rank testing. HPV genotyping was verified using quantitative polymerase chain reaction to validate VirMAP results using receiver operating characteristic curve and Cohen's kappa. RESULTS: At baseline, 42%, 12%, 25%, and 16% of patients were positive for HPV 16, HPV 18, HPV HR, and HPV LR, respectively, and 8% were HPV negative. HPV type was associated with insurance status and CRT response. Patients with HPV 16+ and other HPV HR+ tumors were significantly more likely to have a complete response to CRT versus patients with HPV 18 and HPV LR/HPV-negative tumors. Overall HPV viral loads predominantly decreased throughout CRT, except for HPV LR viral load. CONCLUSIONS: Rarer, less well-studied HPV types in cervical tumors are clinically significant. HPV 18 and HPV LR/negative tumors are associated with poor CRT response. This feasibility study provides a framework for a larger study of intratumoral HPV profiling to predict outcomes in patients with cervical cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sammouri J, Wong MC, Lynn EJ, et al. Serial Genotyping of the Human Papillomavirus in Cervical Cancer: An Insight Into Virome Dynamics During Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 36801350. doi:10.1016/j.ijrobp.2023.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。